Home / Resource Library / First results of a head-to-head trial of acalabrutinib versus ibrutinib in patients with high-risk CLL

First results of a head-to-head trial of acalabrutinib versus ibrutinib in patients with high-risk CLL

ASCO 2021: Results of a phase III study comparing acalabrutinib with ibrutinib for treatment of relapsed CLL.